Silo Pharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Silo Pharma, Inc. (Nasdaq: SILO) on August 18, 2026. The filing discloses the entry into a material definitive agreement and the unregistered sale of equity securities.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The transaction involves a non-cash consideration of 165,000 shares of common stock issued in exchange for assets.
Material Changes and Transaction Details
- Agreement: On August 18, 2026, the Company entered into an Asset Purchase Agreement with Parkview Consulting LLC.
- Assets Acquired: The Company purchased certain software, technology, domain names, and related intellectual property.
- Counterparty Relationship: The Seller is managed by Corwin Yu, who currently serves as the lead strategic advisor on the Company's Cryptocurrency Advisory Board.
- Consideration: The Company issued 165,000 shares of common stock (par value $0.0001) to the Seller.
- Restrictions: The shares are subject to a 12-month lock-up period, or until a Change in Control or written consent is granted, whichever occurs first.
- Legal Basis: The sale was made in reliance on Section 4(a)(2) of the Securities Act of 1933.
Guidance, Risks, and Contingencies
The filing does not contain updated financial guidance or management commentary regarding future outlook. The agreement includes standard representations, warranties, and covenants. The Seller agreed to indemnify the Company against misrepresentations, breaches, third-party infringement claims regarding the software, and acts of gross negligence, fraud, or intentional misconduct.
Key Facts for Investor Verification
- Verify the fair market value of the 165,000 shares issued and the valuation of the acquired software and technology assets.
- Review the full Asset Purchase Agreement (Exhibit 10.1) for specific details on the intellectual property rights transferred.
- Assess the potential conflict of interest or related party nature of the transaction given the Seller's manager's role on the Cryptocurrency Advisory Board.
- Confirm the impact of the share issuance on existing shareholder dilution.